

Medical Director's Visit to Beauty World 2023, Middle East

Playing a crucial role in driving our business goals forward, our Medical Director, Dr. Patel, made a significant impact by attending Beauty World 2023 in the Middle East, held in Dubai from October 30 to November 1.

Dr. Patel's strategic participation in Beauty World not only symbolized our dedication to excellence but also marked a proactive initiative to broaden our footprint in the region.



NovoBliss Family's Festive Spirit:



**A Joyous Blend of Team Lunch and
Diwali Celebrations, Marked by
Outstanding Performances in
Various Diwali Competitions.**



Published Article in PARIPEX - Indian Journal of Research

PARIPEX - INDIAN JOURNAL OF RESEARCH | Volume - 12 | Issue - 11 | November - 2023 | PRINT ISSN No. 2250 - 1991 | DOI : 10.36106/paripex



ORIGINAL RESEARCH PAPER

"BOVINE COLLAGEN SUPPLEMENTATION - EFFECTS ON MUSCLE STRENGTH IN OSTEOARTHRITIS SYMPTOMS RELIEF – A POST HOC ANALYSIS"

Clinical Research

KEY WORDS:

Samrat Warma	Collagen Lifesciences Private Limited, Nashik, Maharashtra, India
Himanshi Warma	Collagen Lifesciences Private Limited, Nashik, Maharashtra, India
Apeksha Merja	NovoBliss Research Private Limited, Ahmedabad, India
Nayan Patel	NovoBliss Research Private Limited, Ahmedabad, India
Maheshvari Patel*	NovoBliss Research Private Limited, Ahmedabad, India *Corresponding Author

<https://www.worldwidejournals.com/paripex/article/bovine-collagen-supplementation-effects-on-muscle-strength-in-osteoarthritis-symptoms-relief-a-post-hoc-analysis/NDEzMDM=?is=1>

Integration of Vita Easyshade Advance 5: A State-of-the-Art Advancement in Technology for Dental Color Measurement

NovoBliss introduces the Vita Easyshade Advance 5, a groundbreaking device revolutionizing dental color measurement technology. This state-of-the-art solution enhances precision in shade determination, benefiting restorative dentistry by providing advanced features for streamlined workflows. The Vita Easyshade Advance 5 excels with multi-angle measurement, digital shade mapping, and compatibility with shade databases, ensuring thorough and systematic shade analysis for dental clinical studies.

Shade Determination using VITA Easyshade Advance V



INSTANTLY DETERMINE AND VERIFY SHADE WITH THE ALL-NEW VITA EASYSHADE V

VITA Easyshade Advance V



Commencing Real-World Evidence (RWE) Exploration

NovoBliss Research is at the forefront of delivering comprehensive end-to-end services for RWE studies. We take pride in announcing the successful completion of few studies as mentioned below:

1. Patient reported outcome study on the efficacy, usage, and safety of test treatment for dry skin management.

This was a post-approval, cross sectional, observational study to assess the clinical impact,

utilization pattern and safety of test product in management of dry skin conditions. A retrospective data of patient's with dry conditions were collected from several clinical sites across India with usage of test treatment. The study population consisted of patients attending the dermatologic outpatient clinics of the participating centres.

2. Assessment of clinical impact, safety, and utilization of test product for daily use in dry, sensitive skin.

This was a post-approval, cross sectional, observational, single arm clinical study to assess the clinical impact, utilization pattern and safety of test treatment for daily use in dry sensitive skin. Patients' data were collected from various clinical sites across India with usage of test treatment.

3. Evaluation of clinical impact, utilization and safety of test product for daily use in acne prone skin through patient reported outcome.

This was a post-approval, cross sectional, observational, single arm clinical study to assess the clinical impact, utilization pattern and safety of test treatment for daily use in acne prone skin. Data from patients were gathered across several clinical sites throughout India, employing the test treatment.

4. A cross-sectional study to assess the clinical impact, safety & utilization of triple drug fixed-dose combination in the management of Type 2 Diabetes Mellitus.

This was a post-approval, cross-sectional, observational study that employed a single-arm design to assess the clinical utilization of triple therapy as a patient-centered approach, specifically when glycemic targets weren't met using traditional anti-diabetic drug.

5. Post Approval, concurrent, observational study to assess safety, clinical utilization and effectiveness of test drug in patients having Coronary Artery Disease undergoing PCI


This post – hoc analyses aimed to assess safety and effectiveness of test drug in primary cases of CAD with Hypertension who underwent PCI. Primary study analyses were carried out at different centres.



Successfully Completed Clinical Studies:


1. Assessment of Comedogenic Potential of Test Products: A Randomized, Evaluator-Blinded Study Using the Patch Test with Cyanoacrylate Follicular Biopsy Method.

In this clinical study, total of 16 subjects were enrolled, out of which 12 subjects completed the study. The study assessed diverse test products, determining their comedogenic potential of the product (scoring 1-3 in one or more subjects) and evaluating the percentage change in microcomedone formation from baseline (Day 1) to Visit 14 (Day 29). Concurrently, safety was assessed through adverse event and serious adverse event occurrences.



Before

No. of Follicles: 59
No. of Comedones: 4
% Coverage: 6.77%
Follicular Biopsy Score: 0.5



After

No. of Follicles: 132
No. of Comedones: 75
% Coverage: 56.81%
Follicular Biopsy Score: 2

2. A Clinical Study of Test Product for its Long-Lasting Effect in Healthy Human Females.

In this clinical study, total of 33 subjects were enrolled, out of which 32 subjects completed the study. The study evaluated the long-lasting effect and smudge-free effect of the test product from the baseline before product application and after product application at T0 hours, T08 hours and T24 hours. Safety of the test product at the periocular region in terms of eye irritation, redness, itchiness, and lachrymation was assessed along with the change in photograph.



Visit 2 (before test product application)



Visit 2 (T15 min of test product application)



Visit 2 (T8 hrs of test product application)



Visit 3 (T24 hrs of test product application)

3. Evaluation of Dermatological Safety of Test Products by 24 Hours Patch Test under Complete Occlusion on Adult Healthy Human Subjects

A total of 26 subjects were enrolled, and 26 subjects has completed the study. Total 17 test products were tested on human subjects with varied skin types i.e. oily, dry, normal and mixed in shared panel of dermal safety testing following BIS:4011-2018 standard.